Response to sunitinib (Sutent) in chemotherapy refractory clear cell ovarian cancer

Response to sunitinib (Sutent) in chemotherapy refractory clear cell ovarian cancer
复制标题

DOI:
10.1016/j.gore.2016.11.001
复制
发表时间:
2016-11-01
影响因子:
1.2
通讯作者:
Gabra, H.
Gabra, H.
中科院分区:
其他
文献类型:
--
作者:
Alifrangis, C.;Thornton, A.;Gabra, H.

文献摘要

被引文献

相似文献

摘要病例描述了舒尼替尼治疗透明细胞卵巢癌的反应。讨论了透明细胞卵巢癌独特的分子特征讨论了使用舒尼替尼时有关剂量和毒性的实用要点
HighlightsCase describes a response to sunitinib in clear cell ovarian cancer.Discussion of unique molecular characteristics of clear cell ovarian cancersPractical points regarding dosing and toxicity when using sunitinib discussed